Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1952 2
1953 1
1957 1
1959 1
1961 1
1964 8
1965 4
1966 7
1967 2
1968 17
1969 10
1970 18
1971 17
1972 27
1973 22
1974 13
1975 20
1976 22
1977 17
1978 24
1979 41
1980 35
1981 41
1982 35
1983 48
1984 45
1985 64
1986 68
1987 57
1988 47
1989 48
1990 69
1991 45
1992 71
1993 76
1994 76
1995 72
1996 85
1997 89
1998 106
1999 109
2000 133
2001 123
2002 144
2003 123
2004 145
2005 171
2006 181
2007 193
2008 214
2009 223
2010 272
2011 291
2012 293
2013 298
2014 320
2015 353
2016 410
2017 363
2018 351
2019 367
2020 406
2021 397
2022 356
2023 333
2024 146

Text availability

Article attribute

Article type

Publication date

Search Results

7,414 results

Results by year

Filters applied: . Clear all
Page 1
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Lenders JW, et al. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. J Clin Endocrinol Metab. 2014. PMID: 24893135
PARTICIPANTS: The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), seven experts in the field, and a methodologist. ...Patients with paraganglioma should be tested for SDHx mutations, and those with metastatic disease fo …
PARTICIPANTS: The Task Force included a chair selected by the Endocrine Society Clinical Guidelines Subcommittee (CGS), seven experts …
Clinical Review and Update on the Management of Thyroid Storm.
De Almeida R, McCalmon S, Cabandugama PK. De Almeida R, et al. Mo Med. 2022 Jul-Aug;119(4):366-371. Mo Med. 2022. PMID: 36118802 Free PMC article. Review.
Thyroid storm is a severe manifestation of thyrotoxicosis. Thyroid storm is diagnosed as a combination of thyroid function studies showing low to undetectable thyroid stimulating hormone (TSH) (<0.01mU/L) with elevated free thyroxine (T4) and/or triiodothyronine (T3), p …
Thyroid storm is a severe manifestation of thyrotoxicosis. Thyroid storm is diagnosed as a combination of thyroid function studies sh …
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Fassnacht M, et al. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467. Eur J Endocrinol. 2016. PMID: 27390021 Free article.
In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent conditions requiring therapeutic intervention (e.g. adrenocortical carcinoma, pheochromocytoma, hormone-producing adenoma or metastasis). ...
In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent conditions requiring therapeutic …
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. Fassnacht M, et al. Eur J Endocrinol. 2018 Oct 1;179(4):G1-G46. doi: 10.1530/EJE-18-0608. Eur J Endocrinol. 2018. PMID: 30299884 Free article.
(B) Which are the best prognostic markers in ACC? (C) Is adjuvant therapy able to prevent recurrent disease or reduce mortality after radical resection? ...(vi) For advanced ACC not amenable to complete surgical resection, local therapeutic measures (e.g. radiation …
(B) Which are the best prognostic markers in ACC? (C) Is adjuvant therapy able to prevent recurrent disease or reduce mortality after …
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC; Karlan BY, Khan S, Klein C, Kohlmann W; CGC; Kurian AW, Laronga C, Litton JK, Mak JS; LCGC; Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC; Senter-Jamieson L; CGC; Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Daly MB, et al. J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001. J Natl Compr Canc Netw. 2021. PMID: 33406487
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Nieman LK, et al. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. J Clin Endocrinol Metab. 2015. PMID: 26222757 Free PMC article.
OBJECTIVE: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. ...The choice of second-line treatments, i …
OBJECTIVE: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS: Participants include an …
The Diagnosis and Treatment of Craniopharyngioma.
Müller HL. Müller HL. Neuroendocrinology. 2020;110(9-10):753-766. doi: 10.1159/000504512. Epub 2019 Nov 4. Neuroendocrinology. 2020. PMID: 31678973 Free article. Review.
If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve the optical and hypothalamic functions. ...Novel insights into neuropsychological sequelae after CP occurrence should be the basis for the developmen …
If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve the optical and …
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.
Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo Madueño G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa AC, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. Timmerman D, et al. Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10. Int J Gynecol Cancer. 2021. PMID: 34112736 Free PMC article. Review.
EAA clinical practice guidelines-gynecomastia evaluation and management.
Kanakis GA, Nordkap L, Bang AK, Calogero AE, Bártfai G, Corona G, Forti G, Toppari J, Goulis DG, Jørgensen N. Kanakis GA, et al. Andrology. 2019 Nov;7(6):778-793. doi: 10.1111/andr.12636. Epub 2019 May 16. Andrology. 2019. PMID: 31099174 Free article.
We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, and administration or abuse of substances associated with GM (1 ). ...We suggest surgical treatment only for patients with long-lasting GM, wh …
We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, an …
Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses.
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Obstet Gynecol. 2016 Nov;128(5):e210-e226. doi: 10.1097/AOG.0000000000001768. Obstet Gynecol. 2016. PMID: 27776072
7,414 results